Improved Progression-Free Survival in patients with short tumor telomere length:
Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC
Another Geron Multi-Center study AACR presentation
Their findings suggested that imetelstat given as maintenance therapy did prolong progression free survival in patients with advanced NSCLC whose tumors have short telomeres. They report that these data are consistent with the hypothesis that clinical benefit from telomerase inhibition is greater in patients with tumors possessing short telomeres.